183 related articles for article (PubMed ID: 9440025)
1. Growth factors in gliomas: antisense and dominant negative mutant strategies.
Campbell JW; Pollack IF
J Neurooncol; 1997 Dec; 35(3):275-85. PubMed ID: 9440025
[TBL] [Abstract][Full Text] [Related]
2. Specific gene suppression using antisense strategy for growth suppression of glioma.
Matsuno A; Nagashima T
Med Electron Microsc; 2004 Sep; 37(3):158-61. PubMed ID: 15449107
[TBL] [Abstract][Full Text] [Related]
3. [Approach to human glioma cells using antisense molecules].
Yoshida S; Tanaka R
No To Shinkei; 1995 Sep; 47(9):823-8. PubMed ID: 7546930
[No Abstract] [Full Text] [Related]
4. [Gene therapy for brain tumors: antitumor effects of introduction of antisense and tumor suppressor gene (series 2)].
Nitta T
No Shinkei Geka; 1994 Oct; 22(10):903-9. PubMed ID: 7969756
[No Abstract] [Full Text] [Related]
5. Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents.
Caruso G; Caffo M
Recent Pat CNS Drug Discov; 2014 Apr; 9(1):2-12. PubMed ID: 24605941
[TBL] [Abstract][Full Text] [Related]
6. Nucleic acid-based technologies in therapy of malignant gliomas.
Piwecka M; Rolle K; Wyszko E; Żukiel R; Nowak S; Barciszewska MZ; Barciszewski J
Curr Pharm Biotechnol; 2011 Nov; 12(11):1805-22. PubMed ID: 21902632
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1].
Kasprzak HA; Trojan J; Bierwagen M; Kopiński P; Jarocki P; Bartczak K; Czapiewska J
Neurol Neurochir Pol; 2006; 40(6):509-15; discussion 516. PubMed ID: 17199177
[TBL] [Abstract][Full Text] [Related]
9. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
Chavany C; Connell Y; Neckers L
Mol Pharmacol; 1995 Oct; 48(4):738-46. PubMed ID: 7476902
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells.
Nitta T; Sato K
Neurosurgery; 1994 Feb; 34(2):309-14; discussion 314-5. PubMed ID: 8177392
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders.
Wang Q; Marini JC
J Clin Invest; 1996 Jan; 97(2):448-54. PubMed ID: 8567966
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas.
Caruso G; Caffo M; Raudino G; Alafaci C; Salpietro FM; Tomasello F
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):53-69. PubMed ID: 19832690
[TBL] [Abstract][Full Text] [Related]
13. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.
Wen PY; Kesari S; Drappatz J
Expert Rev Anticancer Ther; 2006 May; 6(5):733-54. PubMed ID: 16759164
[TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
Hau P; Jachimczak P; Bogdahn U
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
[TBL] [Abstract][Full Text] [Related]
15. An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.
Sugawa N; Ueda S; Nakagawa Y; Nishino H; Nosaka K; Iwashima A; Kurimoto M
J Neurooncol; 1998 Sep; 39(3):237-44. PubMed ID: 9821109
[TBL] [Abstract][Full Text] [Related]
16. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
17. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo.
Kang CS; Zhang ZY; Jia ZF; Wang GX; Qiu MZ; Zhou HX; Yu SZ; Chang J; Jiang H; Pu PY
Cancer Gene Ther; 2006 May; 13(5):530-8. PubMed ID: 16410821
[TBL] [Abstract][Full Text] [Related]
18. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
20. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma.
Julien T; Frankel B; Longo S; Kyle M; Gibson S; Shillitoe E; Ryken T
Surg Neurol; 2000 Apr; 53(4):360-8; discussion 368-9. PubMed ID: 10825522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
